What kind of policy reforms are you looking at to revolutionise the CRO sector? I believe the most meaningful...
Alkem MedTech, a wholly-owned medical devices subsidiary of Alkem Laboratories, has announced the execution of...
DUSQ, a Delhi-based sleep science and recovery startup, has raised Rs 24 crore in seed funding led by Fir...
Corning Incorporated has introduced the Corning Low-Flow Reactor System 2 as the latest product line available...
146 Biosimilars in 25 Years: India at Global Scale
Biosimilars are an important part of modern therapeutics and a central component of India’s shift beyond a generics-led pharmaceutical model. As of December 2025, India has approved 146 biosimilars, giving it one of the largest and most diverse biosimilar portfolios globally. This portfolio has been built by around 33 companies actively engaged in biosimilar development and manufacturing. The Indian biosimilars market was valued at approximately Rs 4.37 billion in 2024 and is expected to grow at a compound annual growth rate of 14.2 per cent, reaching around Rs 16.49 billion by 2034, according to Expert Market Research. Policy initiatives, closer regulatory alignment with global standards, and a growing emphasis on exports are reinforcing biosimilars as a core pillar of India’s evolving pharmaceutical landscape. Let’s look at the current biosimilars landscape in India and how it is evolving.
For Feedback, please email us at: communications@mmactiv.com
Sign up here to access BioSpectrum India Flip Book.
Sign up here to access BioSpectrum India Flip Book
